Satoeya N, Zack SR, Zoubi OA, Umar S, Burgos A, Abdulrab S, et al. Tofacitinib repairs inflammation and mitochondrial dysregulation in GM-CSF reprogrammed RA macrophages. Cell Mol Immunol. 2026;23:417–31.
Casey AM, Ryan DG, Prag HA, Chowdhury SR, Marques E, Turner K, et al. Pro-inflammatory macrophages produce mitochondria-derived superoxide by reverse electron transport at complex I that regulates IL-1β release during NLRP3 inflammasome activation. Nature Metabolism. 2025;7:493–507.
Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Rep. 2019;28:2455–70.e5.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicenter, open-label, phase 4 randomized controlled trial. Lancet. 2021;397:305–17.
Hogan AE, Davis C, Jenkins BJ, Jones N, O’Shea D. Repurposing metabolic drugs as anti-inflammatory agents. Trends Endocrinol Metab. 2025. https://doi.org/10.1016/j.tem.2025.07.003.
Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001;15:557–67.
Fleischmann RM, van der Heijde D, Strand V, Atsumi T, McInnes IB, Takeuchi T, et al. Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomized trials (contRAst 1 and contRAst 2). Ann Rheum Dis. 2023;82:1516–26.
Nijjar JS, Abbott-Banner K, Alvarez Y, Aston N, Bass D, Bentley JH, et al. Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomized, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study. Ann Rheum Dis. 2025;84:856–65.
Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K. Predictors, demographics and frequency of sustained remission and low disease activity in antitumor necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford). 2019;58:2162–9.
Keystone EC, Rampakakis E, Movahedi M, Cesta A, Stutz M, Sampalis JS, et al. Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries. J Rheumatol. 2020;47:510–7.